Biologics APIs

Synthego Aims to Accelerate Drug Discovery with New Engineered Cell Libraries

August 04, 2022

Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.

Progress in the Development of CAR NK-Cell Therapies

August 03, 2022

Further advances in construct design and manufacturing scalability are still needed.

Novasep-PharmaZell Invests €7.3M to Increase API Production Capacity

August 02, 2022

Novasep-PharmaZell will increase API production capacity at its Mourenx site with €7.3M investment.

VeriSIM Life and Mayo Clinic Team Up to Co-develop New Therapies

July 08, 2022

VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.

LG Chem Renews License with Avacta for IND Studies

July 08, 2022

LG Chem has decided to proceed with IND-enabling studies and has renewed a license with Avacta.

ImmunoGen Partners with Oxford BioTherapeutics to Develop Novel ADCs

June 27, 2022

ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.

Lonza, IBF Collaborate to Support Development and Manufacturing of Biologics and Small Molecules

May 26, 2022

Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.

Speeding Up Development for Traditional Biologics

May 03, 2022

Resolving operational bottlenecks makes mAb manufacturing more efficient.

Spectrum Chemical Announces Expansion of bioCERTIFIED Product Portfolio to Support Global Demand for New Vaccines and Therapeutics

March 09, 2022

Spectrum Chemical has further expanded its bioCERTIFIED product portfolio to support the growing global demand for new vaccines and therapeutics.

Alvea to Develop New DNA Vaccine Against SARS-CoV-2 Variants

February 23, 2022

Alvea has begun preclinical testing of a scalable, shelf-stable DNA vaccine against SARS-CoV-2 variants.